CIP
PTGX icon

Chartwell Investment Partners’s Protagonist Therapeutics PTGX Stock Holding History

Chartwell Investment Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,098
Closed -$277K – 440
2023
Q4 		$277K Sell
12,098
-1,646
-12% -$28.8K 0.01% 414
2023
Q3 		$229K Hold
13,744
– – 0.01% 411
2023
Q2 		$380K Buy
+13,744
New +$344K 0.01% 397

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Chartwell Investment Partners's PTGX Position: Q1 2024 in Review

Chartwell Investment Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2024, closing a stake of 12,098 shares — an estimated $277K sold.

Chartwell Investment Partners first reported a position in PTGX in Q2 2023 and held it in 3 quarters. The position peaked at $380K in Q2 2023. 185 funds tracked by Wall St. Rank hold PTGX as of Q1 2024.

  • Chartwell Investment Partners reported no remaining Protagonist Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Chartwell Investment Partners sold 12,098 Protagonist Therapeutics shares in Q1 2024, an estimated $277K.
  • Chartwell Investment Partners first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 3 quarters.
  • Chartwell Investment Partners's Protagonist Therapeutics position peaked at $380K in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2024.

Based on Chartwell Investment Partners's 13F filing for Q1 2024, filed 14 May 2024.